HIV-HBV coinfection among South African patients receiving antiretroviral therapy

Abstract

There are approximately 33 million individuals with HIV infection worldwide. The majority of infections are in southern Africa where hepatitis B is also known to be endemic. As access to life-saving antiretroviral therapy (ART) increases, the possibility for hepatitis B treatment resistance increases because most ART regimens contain lamivudine. Patients coinfected with HBV are therefore receiving monotherapy for HBV infection, leading to possible HBV-resistant mutants and the concurrent public health effect thereof. Additional information is needed on the prevalence of HIV-HBV coinfection and treatment response to ART. We present a summary of the information available from South Africa to date.

Figures

Figure 1

Historical prevalence of HBsAg among Black children in southern Africa Data from [1] and [2]. HBsAg, hepatitis B surface antigen.